免疫检查点抑制剂相关肌炎在癌症患者中的发生率与结局
联合ICI治疗者发生率高于单药治疗(0.94% vs 0.31%,相对风险3.1)。超过半数患者合并重叠表现,重叠综合征患者预后更差,79%出现呼吸衰竭,8例死亡且均合并重症肌无力或心肌炎。
要点
- ICI相关肌炎发生率0.40%,联合治疗者相对风险为单药治疗的3.1倍。
- 53%患者合并重叠表现(心肌炎、重症肌无力或两者兼有)。
- 重叠综合征患者79%出现呼吸衰竭,死亡者均合并重症肌无力或心肌炎。
核心结论
- ICI相关肌炎是一种罕见但严重的不良事件,超过半数患者出现重叠表现且预后不良。
- 单纯ICI相关肌炎患者无因不良事件死亡,但重叠综合征患者可出现呼吸衰竭和死亡。
研究设计与样本
- 回顾性队列研究,纳入2016至2019年在德克萨斯大学MD Anderson癌症中心接受ICIs治疗的9088例癌症患者。
- 通过国际疾病分类代码识别ICI相关肌炎病例,并经病历和病理复核确认。
主要发现
- 重叠表现包括5例心肌炎、5例重症肌无力和9例两者兼有。
- ICI相关肌炎发生率在单药治疗中为0.31%,联合ICI治疗中为0.94%,相对风险3.1(95%CI 1.5-6.1)。
- 重叠综合征患者预后较单纯肌炎患者更差,其中79%出现呼吸衰竭;8例死于ICI相关肌炎,均合并重症肌无力或心肌炎(P < 0.05),其中75%合并感染。
临床怎么用
- 对接受ICI治疗的患者应警惕肌炎发生,尤其联合治疗者风险更高。
- 评估ICI相关肌炎时需排查心肌炎和重症肌无力等重叠综合征,因其与呼吸衰竭和死亡风险相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the incidence of immune checkpoint inhibitor-related myositis (ICI-myositis) in cancer patients receiving ICIs, and to report associated clinical manifestations, patterns of care, and outcomes. METHODS: We identified a retrospective cohort of patients receiving ICIs between 2016 and 2019 seen at the University of Texas MD Anderson Cancer Center. Cases of ICI-myositis were identified using International Classification of Disease codes and confirmed by reviewing medical records and pathology, as available. RESULTS: A total of 9,088 patients received an ICI. Thirty-six patients (0.40%) were identified as having ICI-myositis: 17 patients (47%) with ICI-myositis alone and 19 (53%) with overlap manifestations (5 patients with myocarditis, 5 with myasthenia gravis, and 9 with both). The incidence of ICI-myositis was 0.31% in those receiving ICI monotherapy and 0.94% in those receiving combination ICI therapy (relative risk 3.1 [95% confidence interval 1.5-6.1]). Twenty-five patients (69%) received ≥1 treatment in addition to glucocorticoids: plasmapheresis in 17 patients (47%), intravenous immunoglobulin in 12 (33%), and biologics in 11 (31%). Patients with overlap conditions had worse outcomes than those with myositis alone, and 79% of them developed respiratory failure. Eight patients died as a result of ICI-myositis, and all had overlap syndrome with myasthenia gravis or myocarditis (P < 0.05); 75% of these patients had a concomitant infection. CONCLUSION: ICI-myositis is a rare but severe adverse event. More than half of the patients presented with overlap manifestations and had deleterious outcomes, including respiratory failure and death. None of the patients with ICI-myositis alone died as a result of adverse events. Optimal treatment strategies have yet to be determined.
引用
- Aldrich J, Pundole X, Tummala S, et al. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis Rheumatol. 2021. PMID: 33258544. doi:10.1002/art.41604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。